ArticleOpen medicine (Warsaw, Poland)2021
Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens.
Article in Open medicine (Warsaw, Poland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Is CMV PCR Monitoring Necessary in Patients with Hematological Malignancy Receiving Chemotherapy? A Prospective Single-Center StudyTurkish journal of haematology : official journal of Turkish Society of Haematology · 2026Article
- Distinct immunologic kinetics and cytomegalovirus reactivation incidence with rituximab- versus obinutuzumab-bendamustine in follicular lymphoma: a single-center case series study.Journal of cancer research and clinical oncology · 2025Observational
- Cytomegalovirus reactivation in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy.International journal of hematology · 2025Article
- Primary Adrenal Insufficiency Triggered by Cytomegalovirus Infection after Obinutuzumab Plus Bendamustine Therapy for Follicular Lymphoma.Internal medicine (Tokyo, Japan) · 2025Article
- Severe and/or prolonged COVID-19 in hematologic diseases: clinical implications before and during the omicron era.Frontiers in oncology · 2025Article
- Risk and impact of cytomegalovirus infection in lymphoma patients treated with bendamustine.Annals of hematology · 2024Article
- Effective Neutralizing Antibody Response Against SARS-CoV-2 Virus and Its Omicron BA.1 Variant in Fully Vaccinated Hematological Patients.Clinical and experimental medicine · 2023Article
- Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation.BMC cancer · 2022Article
- Bendamustine: A review of pharmacology, clinical use and immunological effects (Review).Oncology reports · 2022Review
- Severe CMV Infection after Chemo-Immunotherapy with Dose-Reduced Bendamustine and Rituximab in a Mantle Cell Lymphoma Old Patient.Mediterranean journal of hematology and infectious diseases · 2021Article
- Infectious Agents and Bone Marrow Failure: A Causal or a Casual Connection?Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients' age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. In particular, patients who received bendamustine plus rituximab and dexamethasone were at higher risk of CMV reactivation, especially when administered as first-line therapy and after the third course of bendamustine. In addition, patients with CMV reactivation showed a significant depression of circulating CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.